Table 2 Estimates of current malaria infection and exposure.
Category | Characteristic | Study site | ||||
---|---|---|---|---|---|---|
Ungoye | Mfangano | Takawiri | Kibuogi | Ngodhe | ||
Sample size | Number of sample for microscopy | 1238 | 1938 | 883 | 336 | 633 |
Number of sample for PCR | 1237 | 1938 | 883 | 336 | 632 | |
Number of sample for ELISA | 868 | 1574 | 770 | 325 | 575 | |
Blood smear microscopy | Positive for Plasmodium spp., n (%) | 403 (32.6) | 393 (20.3) | 38 (4.3) | 21 (6.3) | 39 (6.2) |
Geometric mean parasite density, parasite/µl (95% CI) | 1101 (942–1286) | 1045 (877–1245) | 1458 (841–2526) | 1665 (641–4326) | 1229 (657–2298) | |
P. falciparum parasite rate in children 2–10 years1, n/N2 (%) | 263/669 (39.3) | 211/846 (24.9) | 24/419 (5.7) | 11/146 (7.5) | 25/234 (10.7) | |
P. falciparum gametocytes rate, n/N3 (%) | 41/397 (10.3) | 34/358 (9.5) | 2/36 (5.6) | 5/21 (23.8) | 3/39 (7.7) | |
PCR | Positive for Plasmodium spp., n (%) | 1048 (84.7) | 1033 (53.3) | 153 (17.3) | 60 (17.9) | 82 (13.0) |
P. falciparum parasite rate in children 2–10 years, n/N2 (%) | 433/669 (64.7) | 366/847 (43.2) | 62/420 (14.8) | 26/146 (17.8) | 35/234 (15.0) | |
ELISA | Median AMA-1 OD (IQR) | 0.89 (0.48–1.08) | 0.79 (0.33–1.06) | 0.35 (0.09–0.82) | 0.48 (0.14–0.92) | 0.40 (0.13–0.83) |
Median AMA-1 antibody titre (IQR) | 1579 (358–5564) | 1001 (189–4083) | 194 (40–1082) | 295 (44–1418) | 225 (47–1025) | |
AMA-1 SCR, (95% CI) | 0.204 (0.181–0.228) | 0.166 (0.153–0.181) | 0.139 (0.123–0.156) | 0.136 (0.113–0.165) | 0.122 (0.106–0.141) | |
AMA-1 estimate EIR4 (95% CI) | 12.1 (8.9–16.2) | 7.1 (5.7–8.9) | 4.4 (3.2–6.0) | 4.2 (2.6–7.0) | 3.2 (2.2–4.6) | |
Median MSP-119 OD (IQR) | 0.30 (0.13–0.81) | 0.33 (0.17–0.79) | 0.19 (0.11–0.43) | 0.20 (0.12–0.51) | 0.18 (0.11–0.43) | |
Median MSP-119 antibody titre (IQR) | 96 (33–580) | 118 (45–530) | 43 (24–162) | 52 (28–217) | 41 (22–131) | |
MSP-119 SCR, (95% CI) | 0.079 (0.070–0.089) | 0.075 (0.069–0.082) | 0.043 (0.037–0.049) | 0.048 (0.039–0.060) | 0.046 (0.039–0.054) | |
MSP-119 estimate EIR4 (95% CI) | 7.1 (5.5–9.2) | 6.4 (5.4–7.7) | 2.0 (1.4–2.6) | 2.5 (1.6–4.0) | 2.3 (1.6–3.2) | |
Median CSP OD (IQR) | 0.40 (0.22–0.68) | 0.41 (0.26–0.72) | 0.24 (0.12–0.41) | 0.29 (0.20–0.44) | 0.24 (0.14–0.40) | |
Median CSP antibody titre (IQR) | 385 (207–834) | 446 (246–946) | 221 (106–406) | 245 (153–433) | 219 (123–422) | |
CSP SCR, (95% CI) | 0.008 (0.006–0.010) | 0.011 (0.010–0.013) | 0.008 (0.006–0.010) | 0.010 (0.007–0.014) | 0.009 (0.007–0.011) |